Jane Street
CHRS icon

Jane Street’s Coherus Oncology CHRS Stock Holding History

Jane Street’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.1K Sell
38,663
-1,831
-5% -$2.99K ﹤0.01% 10896
2026
Q1 		$68.4K Sell
40,494
-563,016
-93% -$1,000K ﹤0.01% 10838
2025
Q4 		$857K Buy
603,510
+393,530
+187% +$573K ﹤0.01% 6457
2025
Q3 		$344K Buy
209,980
+146,667
+232% +$163K ﹤0.01% 8642
2025
Q2 		$46.3K Buy
+63,313
New +$54.7K ﹤0.01% 9199
2025
Q1 		– Sell
-22,246
Closed -$30.7K – 9543
2024
Q4 		$30.7K Sell
22,246
-45,360
-67% -$50.9K ﹤0.01% 9077
2024
Q3 		$70.3K Sell
67,606
-140,867
-68% -$193K ﹤0.01% 9099
2024
Q2 		$361K Sell
208,473
-153,089
-42% -$308K ﹤0.01% 7507
2024
Q1 		$864K Sell
361,562
-192,334
-35% -$473K ﹤0.01% 5677
2023
Q4 		$1.84M Buy
553,896
+315,258
+132% +$844K ﹤0.01% 4471
2023
Q3 		$893K Sell
238,638
-248,995
-51% -$1.15M ﹤0.01% 5351
2023
Q2 		$2.08M Buy
487,633
+380,692
+356% +$2.25M ﹤0.01% 4111
2023
Q1 		$731K Buy
106,941
+93,730
+709% +$727K ﹤0.01% 5629
2022
Q4 		$105K Sell
13,211
-10,596
-45% -$81.5K ﹤0.01% 8067
2022
Q3 		$229K Sell
23,807
-64,002
-73% -$648K ﹤0.01% 7969
2022
Q2 		$635K Buy
87,809
+35,421
+68% +$308K ﹤0.01% 6312
2022
Q1 		$677K Buy
52,388
+35,782
+215% +$455K ﹤0.01% 6914
2021
Q4 		$265K Sell
16,606
-19,784
-54% -$346K ﹤0.01% 8397
2021
Q3 		$585K Sell
36,390
-9,775
-21% -$143K ﹤0.01% 6985
2021
Q2 		$639K Buy
46,165
+21,745
+89% +$308K ﹤0.01% 6778
2021
Q1 		$356K Sell
24,420
-25,260
-51% -$429K ﹤0.01% 7420
2020
Q4 		$863K Buy
49,680
+3,342
+7% +$59.5K ﹤0.01% 4904
2020
Q3 		$850K Buy
+46,338
New +$862K ﹤0.01% 4363
2020
Q1 		– Sell
-12,671
Closed -$228K – 5349
2019
Q4 		$228K Buy
12,671
+1,721
+16% +$31.7K ﹤0.01% 4584
2019
Q3 		$222K Sell
10,950
-8,239
-43% -$165K ﹤0.01% 4534
2019
Q2 		$424K Buy
+19,189
New +$333K ﹤0.01% 3789
2017
Q3 		– Sell
-19,279
Closed -$277K – 4486
2017
Q2 		$277K Buy
+19,279
New +$371K ﹤0.01% 3685

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Jane Street's CHRS Position: Q2 2026 in Review

Jane Street reduced its Coherus Oncology (CHRS) stake by 4.5% in Q2 2026, selling an estimated $2.99K and leaving 38,663 shares worth $54.1K. The position accounts for ﹤0.01% of the portfolio, ranked #10896.

Jane Street first reported a position in CHRS in Q2 2017 and has held it in 27 quarters since. The position peaked at $2.08M in Q2 2023. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Jane Street held 38,663 shares of Coherus Oncology worth $54.1K as of Q2 2026.
  • Jane Street sold 1,831 Coherus Oncology shares in Q2 2026, an estimated $2.99K.
  • Coherus Oncology made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10896 holding.
  • Jane Street first reported a position in Coherus Oncology in Q2 2017 and has held it in 27 quarters since.
  • Jane Street's Coherus Oncology position peaked at $2.08M in Q2 2023.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.